Your email has been successfully added to our mailing list.

×
0.107913669064748 0.107913669064748 0.107913669064748 0.107913669064748 0.0431654676258993 0.0287769784172664 0.0144604316546764 0.0144604316546764
Stock impact report

Selecta Biosciences Presents New Data at 2019 American College of Rheumatology Annual Meeting from Phase 2 Study of SEL-212 for the Treatment of Patients with Chronic Refractory Gout

Selecta Biosciences, Inc. (SELB) 
Last selecta biosciences, inc. earnings: 3/12 08:00 am Check Earnings Report
Company Research Source: GlobeNewswire
– Data demonstrate SEL-212 efficacy, reduction in the incidence of gout flares and support for dose selection in the ongoing head-to-head COMPARE trial and in future Phase 3 clinical studies – – Enrollment in the COMPARE trial expected to complete by the end of 2019; interim data to be reported in Q1 2020, and top-line statistical superiority data expected by mid-2020 – WATERTOWN, Mass., Nov. 11, 2019 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced new data from their Phase 2 dose-ranging study evaluating SEL-212, a combined therapy of ImmTOR + pegadricase for the treatment of chronic refractory gout. Results reinforce that, in the five monthly combination cohorts, SEL-212 is effective in reducing incidence of gout flares and supports dose selection in the head-to-head COMPARE clinical trial a Show less Read more
Impact Snapshot
Event Time:
SELB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for SELB alerts
Opt-in for
SELB alerts

from News Quantified
Opt-in for
SELB alerts

from News Quantified